Lu AA24530

From Self-sufficiency
Jump to: navigation, search
Lu AA24530
Systematic (IUPAC) name
CAS Number ?
ATC code none
PubChem CID ?
Chemical data
Formula ?
Molar mass ?
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Lu AA24530 is a antidepressant currently under development by Lundbeck and Takeda for the treatment of major depressive disorder.[1][2] As of March 2010 it is in phase III clinical trials.[3] Lu AA24530 acts as a monoamine reuptake inhibitor (reportedly serotonin according to one source), 5-HT2C receptor antagonist, and 5-HT3 receptor antagonist.[4][5] An NDA is not expected to be submitted to the FDA until at least 2012.[1]

See also


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

  1. 1.0 1.1 "Development programme - Lundbeck". 
  2. "Search of: Lu AA24530 - List Results -". 
  3. "Lundbeck and Takeda finalise plans to initiate phase III pivotal clinical trials with Lu AA21004 and Lu AA24530 (March 3, 2010) | 2010 | Newsroom | Takeda Pharmaceutical Company Limited". 
  4. "Lu AA24530 shows positive results in major depressive disorder phase II study - FierceBiotech". 
  5. "Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD --".